Literature DB >> 24662036

Transcriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasis.

Amit Kumar1, Manisha Vaish2, Rajiv R Ratan3.   

Abstract

Huntington's disease (HD) is a signature polyglutamine disorder. An enduring theory of HD pathogenesis has involved dysregulation of transcription. Indeed, transcriptional regulatory proteins can be modulated to overcome cardinal features of HD-modeled mice, and efforts to move these into human studies are ongoing. Here, we discuss a unifying hypothesis emerging from these studies, which is that HD represents the pathological disruption of evolutionarily conserved adaptive gene programs to counteract oxidative stress, mitochondrial dysfunction and accumulation of misfolded proteins. Transcriptional dyshomeostasis of adaptive genes is further exacerbated by repression of genes involved in normal synaptic activity or growth factor signaling.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24662036      PMCID: PMC4082751          DOI: 10.1016/j.drudis.2014.03.016

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  67 in total

1.  Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences.

Authors:  Tamara Milakovic; Rodrigo A Quintanilla; Gail V W Johnson
Journal:  J Biol Chem       Date:  2006-09-13       Impact factor: 5.157

2.  Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.

Authors:  Libin Cui; Hyunkyung Jeong; Fran Borovecki; Christopher N Parkhurst; Naoko Tanese; Dimitri Krainc
Journal:  Cell       Date:  2006-10-06       Impact factor: 41.582

Review 3.  Mechanisms of disease: Histone modifications in Huntington's disease.

Authors:  Ghazaleh Sadri-Vakili; Jang-Ho J Cha
Journal:  Nat Clin Pract Neurol       Date:  2006-06

4.  Sp1 regulates human huntingtin gene expression.

Authors:  Ruitao Wang; Yawen Luo; Philip T T Ly; Fang Cai; Weihui Zhou; Haiyan Zou; Weihong Song
Journal:  J Mol Neurosci       Date:  2012-03-08       Impact factor: 3.444

5.  Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity.

Authors:  A Giralt; M Puigdellívol; O Carretón; P Paoletti; J Valero; A Parra-Damas; C A Saura; J Alberch; S Ginés
Journal:  Hum Mol Genet       Date:  2011-11-24       Impact factor: 6.150

6.  Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse.

Authors:  G Sadri-Vakili; A S Menon; L A Farrell; C E Keller-McGandy; I Cantuti-Castelvetri; D G Standaert; S J Augood; G J Yohrling; J-H J Cha
Journal:  Eur J Neurosci       Date:  2006-06       Impact factor: 3.386

7.  Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective.

Authors:  Zhihua Qiu; Fran Norflus; Bhupinder Singh; Mary K Swindell; Rodica Buzescu; Michelle Bejarano; Raman Chopra; Birgit Zucker; Caroline L Benn; Derek P DiRocco; Jang-Ho J Cha; Robert J Ferrante; Steven M Hersch
Journal:  J Biol Chem       Date:  2006-04-04       Impact factor: 5.157

8.  PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.

Authors:  Taiji Tsunemi; Travis D Ashe; Bradley E Morrison; Kathryn R Soriano; Jonathan Au; Ruben A Vázquez Roque; Eduardo R Lazarowski; Vincent A Damian; Eliezer Masliah; Albert R La Spada
Journal:  Sci Transl Med       Date:  2012-07-11       Impact factor: 17.956

9.  Promoters are differentially sensitive to N-terminal mutant huntingtin-mediated transcriptional repression.

Authors:  Matthew Hogel; Robert B Laprairie; Eileen M Denovan-Wright
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

10.  Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease.

Authors:  Karen N McFarland; Sudeshna Das; Ting Ting Sun; Dmitri Leyfer; Eva Xia; Gavin R Sangrey; Alexandre Kuhn; Ruth Luthi-Carter; Timothy W Clark; Ghazaleh Sadri-Vakili; Jang-Ho J Cha
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

View more
  22 in total

1.  Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.

Authors:  Robert B Laprairie; Amina M Bagher; Jillian L Rourke; Adel Zrein; Elizabeth A Cairns; Melanie E M Kelly; Christopher J Sinal; Pushkar M Kulkarni; Ganesh A Thakur; Eileen M Denovan-Wright
Journal:  Neuropharmacology       Date:  2019-03-30       Impact factor: 5.250

2.  Huntington's disease: from disease mechanisms to therapies.

Authors:  Craig Blackstone
Journal:  Drug Discov Today       Date:  2014-04-30       Impact factor: 7.851

3.  Impaired import: how huntingtin harms.

Authors:  Elizabeth A Jonas
Journal:  Nat Neurosci       Date:  2014-06       Impact factor: 24.884

4.  Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.

Authors:  Biswarathan Ramani; Bharat Panwar; Lauren R Moore; Bo Wang; Rogerio Huang; Yuanfang Guan; Henry L Paulson
Journal:  Hum Mol Genet       Date:  2017-09-01       Impact factor: 6.150

5.  Mutant Huntingtin Causes a Selective Decrease in the Expression of Synaptic Vesicle Protein 2C.

Authors:  Chaohua Peng; Gaochun Zhu; Xiangqian Liu; He Li
Journal:  Neurosci Bull       Date:  2018-04-30       Impact factor: 5.203

6.  Hydrogen sulfide is neuroprotective in Alzheimer's disease by sulfhydrating GSK3β and inhibiting Tau hyperphosphorylation.

Authors:  Daniel Giovinazzo; Biljana Bursac; Juan I Sbodio; Sumedha Nalluru; Thibaut Vignane; Adele M Snowman; Lauren M Albacarys; Thomas W Sedlak; Roberta Torregrossa; Matthew Whiteman; Milos R Filipovic; Solomon H Snyder; Bindu D Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-26       Impact factor: 12.779

7.  Real-time imaging of Huntingtin aggregates diverting target search and gene transcription.

Authors:  Li Li; Hui Liu; Peng Dong; Dong Li; Wesley R Legant; Jonathan B Grimm; Luke D Lavis; Eric Betzig; Robert Tjian; Zhe Liu
Journal:  Elife       Date:  2016-08-03       Impact factor: 8.140

8.  An Intrabody Drug (rAAV6-INT41) Reduces the Binding of N-Terminal Huntingtin Fragment(s) to DNA to Basal Levels in PC12 Cells and Delays Cognitive Loss in the R6/2 Animal Model.

Authors:  I Alexandra Amaro; Lee A Henderson
Journal:  J Neurodegener Dis       Date:  2016-08-10

Review 9.  Juvenile Huntington's Disease and Other PolyQ Diseases, Update on Neurodevelopmental Character and Comparative Bioinformatic Review of Transcriptomic and Proteomic Data.

Authors:  Karolina Świtońska-Kurkowska; Bart Krist; Joanna Delimata; Maciej Figiel
Journal:  Front Cell Dev Biol       Date:  2021-07-01

10.  Impact of differential and time-dependent autophagy activation on therapeutic efficacy in a model of Huntington disease.

Authors:  Per Ludvik Brattås; Bob A Hersbach; Sofia Madsen; Rebecca Petri; Johan Jakobsson; Karolina Pircs
Journal:  Autophagy       Date:  2020-05-06       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.